Bright Minds Corp (DRUG) - מקדם חוב לטווח ארוך להון

Bright Minds Biosciences (DRUG) is developing modified psychedelics to combat depression, eliminating hallucinogenic side effects through precise chemical tuning. The business relies on global logistics for rare components, which mitigates regulatory risks and maintains high profitability. This price chart on GURU.Markets, where the metric stands at 0.00, illustrates the trading dynamics and complements data on the implementation of robots for accelerated molecular analysis of new compounds.

This ratio determines the issuer's financial autonomy by measuring long-term liabilities relative to equity to assess resilience against rising interest rates. By analyzing the ratio of long-term loans to equity, an investor can evaluate the liquidity shortage risk for Bright Minds Biosciences (DRUG) amid a lack of revenue and highly speculative expectations regarding upcoming clinical trials.